← All trials
NCT05518487
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 10, 2022
- Primary completion
- Jul 15, 2023
- Completion date
- Jul 15, 2024
- First posted
- Aug 26, 2022
- Last posted
- Nov 4, 2022
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Icahn School of Medicine at Mount SinaiStudy chair
- Johns Hopkins UniversityCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- Johns Hopkins UniversityStudy chair
- PPDCollaborator
- Sanofi-AventisCollaborator
- Johns Hopkins UniversityOfficial
- Icahn School of Medicine at Mount SinaiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.